FrancophonIA/ELRC3.0 huggingface dataset:
English: Based on safety and tolerability data, the dose of pazopanib should be reduced to 200 mg once daily in subjects with moderate hepatic impairment (see section 4.2).
Croatian: Temeljem podataka o sigurnosti i podnošljivosti, dozu pazopaniba treba smanjiti na 200 mg jednom dnevno u osoba s umjerenim oštećenjem funkcije jetre (vidjeti dio 4.2).
English: PRES/RPLS can present with headache, hypertension, seizure, lethargy, confusion, blindness and other visual and neurological disturbances, and can be fatal.
Croatian: PRES/RPLS mogu se prezentirati kao glavobolja, hipertenzija, epileptički napadaji, letargija, konfuzija, sljepoća ili neki drugi poremećaj vida ili neurološki poremećaj, a mogu imati i smrtni ishod.
English: When using pazopanib, baseline and periodic monitoring of electrocardiograms and maintenance of electrolytes (e.g. calcium, magnesium, potassium) within normal range is recommended.
Croatian: Kod uzimanja pazopaniba preporučuje se početno mjerenje i povremeno praćenje elektrokardiograma kao i održavanje elektrolita (npr. kalcij, magnezij, kalij) unutar raspona normalnih vrijednosti.
English: Results from population pharmacokinetic modelling (data from subjects with baseline CLCR values ranging from 30.8 ml/min to 150 ml/min) indicated that renal impairment is unlikely to have clinically relevant effect on pazopanib pharmacokinetics.
Croatian: Rezultati populacijskog farmakokinetičkog modeliranja (podaci od ispitanika s inicijalnim vrijednostima klirensa kreatinina u rasponu od 30,8 ml/min do 150 ml/min) ukazuju da oštećenje bubrega vjerojatno nema klinički značajan učinak na farmakokinetiku pazopaniba.
English: VEG108844 achieved its primary endpoint of PFS and demonstrated that pazopanib was non-inferior to sunitinib, as the upper bound of the 95% CI for the hazard ratio was less than the protocol-specified non-inferiority margin of 1.25.
Croatian: Ispitivanje VEG 108844 postiglo je PFS primarnu mjeru ishoda, i pokazalo je da je pazopanib neinferioran sunitinibu, uz gornju granicu intervala pouzdanosti od 95% za omjer hazarda koji je bio manji od onog definiranog planom ispitivanja s marginom neinferiornosti postavljenoj kao 1,25.
English: If the concomitant use of a proton-pump inhibitor (PPI) is medically necessary, it is recommended that the dose of pazopanib be taken without food once daily in the evening concomitantly with the PPI.
Croatian: Ukoliko je istodobna primjena inhibitora protonske pumpe (IPP) medicinski neophodna, preporučuje se uzeti pazopanib bez hrane jednom dnevno, navečer, istodobno s inhibitorom protonske pumpe.
English: In each treatment group, there was a slightly greater percentage of subjects in the 2+ lines of prior systemic therapy for advanced disease (58% and 55%, respectively, for placebo and pazopanib treatment arms) compared with 0 or 1 lines of prior systemic therapy (42% and 45%, respectively, for placebo and pazopanib treatment arms).
Croatian: U svakoj terapijskoj skupini, bio je malo veći postotak ispitanika s 2+ linije prethodne sistemske terapije za uznapredovalu bolest (58% i 55% za placebo i pazopanib krakove) u usporedbi s 0 ili 1 linijom prethodne sistemske terapije (42% odnosno 45% za placebo odnosno pazopanib krakove).
English: Median (weeks)
Croatian: Medijan (tjedni)
English: Group
Croatian: Grupa
English: In vitro studies with human liver microsomes showed that pazopanib inhibited CYP enzymes 1A2, 3A4, 2B6, 2C8, 2C9, 2C19, and 2E1.
Croatian: Ispitivanja in vitro na ljudskim mikrosomima jetre pokazala su da pazopanib inhibira CYP enzime 1A2, 3A4, 2B6, 2C8, 2C9, 2C19, i 2E1.
English: Elimination is primarily via faeces with renal elimination accounting for <4% of the administered dose.
Croatian: Eliminacija je primarno putem stolice dok na eliminaciju putem bubrega otpada <4% primijenjene doze.
English: Effects of pazopanib on other medicinal products
Croatian: Učinci pazopaniba na druge lijekove
English: QT prolongation and torsade de pointes
Croatian: Produljenje QT intervala i „torsade de pointes“
English: In a randomised study comparing pazopanib and sunitinib in RCC (VEG108844), subjects had baseline and follow up LVEF measurements.
Croatian: U randomiziranom ispitivanju u kojem su se uspoređivali pazopanib i sunitinib u liječenju RCC-a (VEG108844), ispitanicima se mjerio LVEF na početku liječenja te u periodu praćenja.
English: Overall Survival Median (months) (95% CI)
Croatian: Ukupno preživljenje Medijan (mjeseci) (95% CI)
English: Clinical pharmacology studies, using pazopanib 800 mg once daily, have demonstrated that pazopanib does not have a clinically relevant effect on the pharmacokinetics of caffeine (CYP1A2 probe substrate), warfarin (CYP2C9 probe substrate), or omeprazole (CYP2C19 probe substrate) in cancer patients.
Croatian: Klinička farmakološka ispitivanja s jednom dnevnom dozom pazopaniba od 800 mg pokazala su da pazopanib nema klinički značajan učinak na farmakokinetiku kofeina (probni supstrat za CYP1A2), varfarina (probni supstrat za CYP2C9), ili omeprazola (probni supstrat za CYP2C19) u bolesnika oboljelih od raka.
English: All patients had clear cell histology or predominantly clear cell histology.
Croatian: Svi bolesnici imali su histološki karcinom svijetlih stanica (engl. clear cell) ili predominantno karcinom svijetlih stanica.
English: Proliferative hepatic lesions (eosinophilic foci and adenoma) were seen in female mice at exposures 2.5 times human exposure based on AUC.
Croatian: Proliferativne jetrene lezije (eozinofilni fokusi i adenomi) zabilježeni su u ženskih miševa pri izloženosti 2,5 puta većoj od one u ljudi prema AUC-u.
English: Liver function should be monitored in all subjects receiving pazopanib, regardless of genotype or age (see section 5.1).
Croatian: Jetrenu funkciju treba pratiti u svih ispitanika koji uzimaju pazopanib, neovisno o genotipu ili dobi (vidjeti dio 5.1).
English: A total of 369 patients with advanced STS were randomised to receive pazopanib 800 mg once daily or placebo.
Croatian: Ukupno 369 bolesnika s uznapredovalim STS-om randomizirano je kako bi primili pazopanib 800 mg jednom dnevno ili placebo.
English: Normal hepatic function
Croatian: Normalna funkcija jetre
English: The primary analysis of the primary endpoint PFS is based on disease assessment by independent radiological review in the entire study population (treatment-naïve and cytokine pre-treated).
Croatian: Primarna analiza primarne mjere ishoda PFS temeljena je na neovisnoj radiološkoj evaluaciji bolesti za cijelu ispitivanu populaciju (bez ranije terapije i s ranijom terapijom citokinima).
English: Pazopanib did not cause genetic damage when tested in genotoxicity assays (Ames assay, human peripheral lymphocyte chromosome aberration assay and rat in vivo micronucleus).
Croatian: Pazopanib nije uzrokovao genetička oštećenja pri testovima genotoksičnosti (Amesov test, test kromosomskih aberacija u humanim perifernim limfocitima te in vivo mikronukleusima štakora).
English: - if you have or have had an aneurysm (enlargement and weakening of a blood vessel wall) or a tear in a blood vessel wall.
Croatian: - ako imate ili ste imali aneurizmu (proširenje i slabljenje stijenke krvne žile) ili rascjep stijenke krvne žile.
English: Blurry or impaired vision
Croatian: Zamagljeni ili oslabljeni vid
English: In two-year carcinogenicity studies with pazopanib, there were increased numbers of liver adenomas noted in mice and duodenal adenocarcinomas noted in rats.
Croatian: U dvogodišnjim ispitivanjima kancerogenosti pazopaniba zabilježen je povećan broj adenoma jetre u miševa i adenokarcinoma duodenuma u štakora.
English: Pazopanib should be used with caution in patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medicinal products that may prolong QT interval and in patients with relevant pre-existing cardiac disease.
Croatian: Pazopanib se treba koristiti s posebnim oprezom u bolesnika koji su ranije već imali produljenje QT intervala, u bolesnika koji primaju terapiju antiaritmicima ili drugim lijekovima koji mogu produljiti QT interval i u bolesnika s od ranije poznatom značajnom bolesti srca.
English: What Votrient contains - The active substance is pazopanib (as hydrochloride).
Croatian: Što Votrient sadrži - Djelatna tvar je pazopanib (u obliku pazopanibklorida).
English: 200 mg OD 9.4
Croatian: 200 mg JD 9,4
English: In repeat dose studies in rodents, effects in a variety of tissues (bone, teeth, nail beds, reproductive organs, haematological tissues, kidney and pancreas) appear related to the pharmacology of VEGFR inhibition and/or disruption of VEGF signalling pathways, with most effects occurring at plasma exposure levels below those observed in the clinic.
Croatian: U ispitivanjima s ponovljenim dozama na glodavcima čini se da su učinci na različita tkiva (kost, zubi, baze noktiju, reproduktivni organi, hematološka tkiva, bubrezi i gušterača) povezani s farmakologijom inhibicije VEGFR-a i/ili poremećajem signalnih puteva VEGF-a, s najviše učinaka pri nižim razinama izloženosti u plazmi od onih kliničkih.
English: The primary objective of the study was to evaluate and compare the two treatment arms for progression-free survival (PFS) and the principle secondary endpoint was overall survival (OS).
Croatian: Primarna mjera ishoda ispitivanja bila je procijeniti i usporediti dvije terapijske skupine prema preživljenju bez progresije bolesti (PFS od engl. progression-free survival), a glavna sekundarna mjera ishoda bilo je sveukupno preživljenje (OS od engl. overall survival).
English: Some patients however may have systemic pazopanib exposure greater than what has been observed after administration of 800 mg pazopanib alone.
Croatian: Međutim, u nekih bolesnika sistemska izloženost pazopanibu može biti veća nego što je zabilježena nakon primjene samog pazopaniba u dozi od 800 mg jednom na dan.
English: Patients should be carefully monitored for clinical signs or symptoms of congestive heart failure.
Croatian: Bolesnike treba pomno nadzirati radi uočavanja kliničkih znakova i simptoma kongestivnog zatajenja srca.
English: In VEG108844, patients (N = 1110) with locally advanced and/or metastatic RCC who had not received prior systemic therapy, were randomised to receive either pazopanib 800 mg once daily continuously or sunitinib 50 mg once daily in 6-week cycles of dosing with 4 weeks on treatment followed by 2 weeks without treatment.
Croatian: U ispitivanju VEG108844, bolesnici (N = 1110) s lokalno uznapredovalim metastazirajućim RCC-om, a koji ranije nisu primali sistemsku terapiju, randomizirani su u skupinu koja je primala ili kontinuirano 800 mg pazopaniba jednom dnevno, ili 50 mg sunitiniba u ciklusima od šest tjedana, a unutar ciklusa terapija je bila dozirana tijekom 4 tjedna nakon čega su slijedila 2 tjedna bez terapije.
English: The decision to resume pazopanib after surgery should be based on clinical judgement of adequate wound healing.
Croatian: Odluku o nastavku terapije nakon kirurškog zahvata treba temeljiti na kliničkoj procjeni odgovarajućeg cijeljenja rane.
English: Endpoints / study population
Croatian: Mjere ishoda / studijska populacija
English: Permanently discontinue pazopanib.
Croatian: Trajno prekinuti liječenje pazopanibom.
English: In juvenile toxicity studies, when pre-weaning rats were dosed from day 9 post partum through to day 14 post partum, pazopanib caused mortalities and abnormal organ growth/maturation in kidney, lung, liver and heart, at a dose approximately 0.1 times the clinical exposure based on AUC in adult humans.
Croatian: U ispitivanjima juvenilne toksičnosti, kada su štakori dozirani od 9. do 14. dana nakon rođenja, pazopanib je uzrokovao smrtnost i abnormalan rast/sazrijevanje organa bubrega, pluća, jetre i srca, pri dozi od približno 0,1 puta kliničke izloženosti na temelju AUC-a u odraslih ljudi.
English: Pazopanib should be discontinued if there is evidence of hypertensive crisis or if hypertension is severe and persists despite anti-hypertensive therapy and pazopanib dose reduction.
Croatian: Liječenje pazopanibom treba trajno prekinuti u slučaju dokazane hipertenzivne krize ili teške hipertenzije koja traje unatoč antihipertenzivnoj terapiji i smanjenju doze pazopaniba.
English: Therefore, no dose adjustment is required in patients with creatinine clearance above 30 ml/min.
Croatian: Stoga, nije potrebna prilagodba doze u bolesnika s klirensom kreatinina većim od 30 ml/min.
English: Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
Croatian: Votrient je indiciran za liječenje odraslih bolesnika s određenim podtipovima uznapredovalog sarkoma mekih tkiva (STS; engl. soft tissue sarcoma) koji su prethodno primili kemoterapiju za metastatsku bolest ili su imali progresiju unutar 12 mjeseci nakon (neo)adjuvantne terapije.
English: Dosing recommendations in hepatically impaired patients are based on pharmacokinetic studies of pazopanib in patients with varying degrees of hepatic dysfunction (see section 5.2).
Croatian: Preporuke za doziranje u bolesnika s oštećenjem jetre se temelje na farmakokinetičkim ispitivanjima pazopaniba u bolesnika s različitim stupnjevima poremećaja funkcije jetre (vidjeti dio 5.2).
English: Disease characteristics at initial diagnosis and at screening were balanced between the treatment arms with the majority of patients having clear cell histology and Stage IV disease.
Croatian: Svojstva bolesti pri inicijalnoj dijagnozi kao i pri probiru raspoređene su između terapijskih krakova tako da je većina bolesnika histološki imala karcinom svijetlih stanica i bolest IV stadija.
English: How to store Votrient
Croatian: Kako čuvati Votrient
English: CYP3A4, P-gp, BCRP inducers
Croatian: Induktori CYP3A4, P-gp-a, BCRP-a
English: In preclinical experiments, pazopanib dose-dependently inhibited ligand-induced auto-phosphorylation of VEGFR-2, c-Kit and PDGFR- receptors in cells.
Croatian: U pretkliničkim pokusima, pazopanib je ovisno o dozi u stanicama inhibirao autofosforilaciju induciranu ligandom VEGFR-2, c-Kit i PDGFR- receptora.
English: Symptoms include: - loss of speech - change of vision - seizure (fits) - confusion - high blood pressure
Croatian: Simptomi uključuju: - gubitak sposobnosti govora - promjene vida - napadaje - smetenost - visoki krvni tlak
English: Cardiac dysfunction/heart failure, heart attack
Croatian: Disfunkcija srca/zatajenje srca, srčani udar
English: Selection of an alternative concomitant medication with no or minimal enzyme or transporter induction potential is recommended.
Croatian: Preporučuje se odabir istodobne alternativne terapije lijekovima bez ili s minimalnim potencijalom stimuliranja enzima ili prijenosa.
English: Transaminase elevation between 3 and 8 x ULN
Croatian: Porast vrijednosti transaminaza na 3-8 x GGN
English: In a rat male fertility study, there was no effect on mating or fertility, but decreased testicular and epididymal weights were noted with reductions in sperm production rates, sperm motility, and epididymal and testicular sperm concentrations observed at exposures 0.3 times human exposure based on AUC.
Croatian: U ispitivanju muške plodnosti u štakora nije bilo učinaka na parenje ili plodnost, ali zabilježene su smanjene težine testisa i epididimisa kao i smanjenje brzine proizvodnje sperme, motilitet spermatozoida i smanjenje koncentracije sperme u epididimisu i testisima i to pri izloženosti od 0,3 puta vrijednosti izloženosti u ljudi temeljem AUC-a.
English: Pazopanib is an orally administered, potent multi-target tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3, platelet-derived growth factor (PDGFR) -α and -β, and stem cell factor receptor (c-KIT), with IC50 values of 10, 30, 47, 71, 84 and 74 nM, respectively.
Croatian: Pazopanib je lijek za peroralnu primjenu koji je snažni višestruki inhibitor tirozin kinaze receptora vaskularnog endotelnog čimbenika rasta (VEGFR)-1, -2, i -3, receptora trombocitnog čimbenika rasta (PDGFR) -α i -β, odnosno receptora čimbenika matičnih stanica (c-KIT), s vrijednostima IC50 od 10, 30, 47, 71, 84 odnosno 74 nM.
English: Interstitial lung disease (ILD)/Pneumonitis
Croatian: Intersticijska bolest pluća/pneumonitis
English: Pooled data from the pivotal STS study (VEG110727, n=369) and the supportive Phase II study (VEG20002, n=142) was evaluated in the overall evaluation of safety and tolerability of pazopanib (total safety population n=382) in subjects with STS (see section 5.1).
Croatian: Združeni podaci iz ključnog ispitivanja STS-a (VEG110727, n=369) i pratećeg ispitivanja faze II (VEG20002, n=142) procijenjeni su u sveukupnoj procjeni sigurnosti i podnošljivosti pazopaniba (sveukupna populacija za procjenu sigurnosti n=382) u ispitanika s STS-om (vidjeti dio 5.1).
English: Results from a meta-analysis using pooled data from clinical studies with pazopanib show that ALT >3x ULN was reported in 126/895 (14%) of patients who did not use statins, compared with 11/41 (27%) of patients who had concomitant use of simvastatin (p = 0.038).
Croatian: Rezultati meta-analize koji su uključili udružene podatke iz kliničkih ispitivanja s pazopanibom pokazuju da je ALT >3 x GGN zabilježen u 126/895 (14%) bolesnika koji nisu uzimali statine u usporedbi s 11/41 (27%) bolesnika koji su istodobno uzimali simvastatin (p=0,038).
English: Women of childbearing potential should be advised to use adequate contraception during treatment and for at least 2 weeks after the last dose of pazopanib and to avoid becoming pregnant while receiving treatment with pazopanib.
Croatian: Žene reproduktivne dobi treba savjetovati da tijekom liječenja i najmanje 2 tjedna nakon posljednje doze pazopaniba koriste adekvatne metode kontracepcije i izbjegavaju trudnoću tijekom liječenja pazopanibom.
English: Patients (N = 435) with locally advanced and/or metastatic RCC were randomised to receive pazopanib 800 mg once daily or placebo.
Croatian: Bolesnici (N = 435) s lokalno uznapredovalim i/ili metastazirajućim RCC-om randomizirani su u skupine za primanje pazopaniba 800 mg jednom dnevno ili placeba.
English: Pazopanib has not been studied in patients who had a history of haemoptysis, cerebral haemorrhage or clinically significant gastrointestinal (GI) haemorrhage in the past 6 months.
Croatian: Pazopanib nije ispitivan u bolesnika koji tijekom proteklih šest mjeseci u anamnezi imaju hemoptizu, cerebralno krvarenje ili klinički značajno gastrointestinalno (GI) krvarenje.
English: Your doctor will monitor your blood pressure while you are taking Votrient.
Croatian: Vaš liječnik će pratiti Vaš krvni tlak za vrijeme uzimanja lijeka Votrient.
English: Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis and discontinue pazopanib in patients developing ILD or pneumonitis.
Croatian: Potrebno je pratiti bolesnike zbog plućnih simptoma koji upućuju na intersticijsku bolest pluća/pneumonitis te prekinuti terapiju pazopanibom u bolesnika kod kojih se razviju intersticijska bolest pluća ili pneumonitis.
English: Patients with only a mild indirect hyperbilirubinaemia, known or suspected Gilbert's syndrome, and elevation in ALT >3 x ULN should be managed as per the recommendations outlined for isolated ALT elevations.
Croatian: Bolesnike koji imaju samo blagu indirektnu hiperbilirubinemiju, za koje se zna ili sumnja da imaju Gilbertov sindrom, i koji imaju povišene vrijednosti ALT-a >3 x GGN treba liječiti sukladno preporukama navedenim za izolirane poraste vrijednosti ALT-a.
English: These results indicate that the bioavailability and the rate of pazopanib oral absorption are increased after administration of the crushed tablet relative to administration of the whole tablet (see section 4.2).
Croatian: Ti podaci ukazuju da se bioraspoloživost i brzina peroralne apsorpcije pazopaniba povećava nakon primjene izmrvljene tablete u usporedbi s primjenom cijele tablete (vidjeti dio 4.2).
English: The safety, efficacy and quality of life of pazopanib versus sunitinib was evaluated in a randomised, open-label, parallel group Phase III non-inferiority study (VEG108844).
Croatian: Sigurnost, djelotvornost i kvaliteta života tijekom liječenja pazopanibom u odnosu na one tijekom liječenja sunitinibom bile su procjenjivane u randomiziranom, otvorenom ispitivanju neinferiornosti faze III s paralelnim skupinama (VEG108844).
English: The risks and benefits of pazopanib should be considered before beginning therapy in patients who have pre-existing cardiac dysfunction.
Croatian: Potrebno je razmotriti rizike i koristi primjene pazopaniba prije započinjanja terapije u bolesnika koji imaju već postojeću disfunkciju srca.
English: Laboratory abnormalities were reported as adverse events less frequently by investigators than as indicated by laboratory value tables.
Croatian: Poremećaje laboratorijskih vrijednosti ispitivači su, kao štetni događaj, rjeđe prijavili nego što je navedeno u tablicama laboratorijskih vrijednosti.
English: If pazopanib is used during pregnancy, or if the patient becomes pregnant whilst receiving pazopanib, the potential hazard to the foetus should be explained to the patient.
Croatian: U slučaju da se pazopanib koristi tijekom trudnoće ili ako bolesnica zatrudni dok je na terapiji pazopanibom, bolesnici se treba objasniti moguća opasnost za fetus.
English: Caution is advised in patients with creatinine clearance below 30 ml/min as there is no experience of pazopanib in this patient population (see section 4.2).
Croatian: Preporučuje se oprez u bolesnika s klirensom kreatinina ispod 30 ml/min jer ne postoje iskustva o primjeni pazopaniba u toj populaciji bolesnika (vidjeti dio 4.2).
English: Pazopanib should be administered at least 1 hour before or 2 hours after administration of short-acting antacids.
Croatian: Pazopanib treba uzeti najmanje 1 sat prije ili 2 sata nakon primjene antacida kratkog djelovanja.
English: Co-administration with potent P-gp or BCRP inhibitors may also alter the exposure and distribution of pazopanib, including distribution into the central nervous systems (CNS).
Croatian: Istovremena primjena s potentnim inhibitorima P-gp-a ili BCRP-a također može promijeniti izloženost i distribuciju pazopaniba, uključujući i distribuciju u središnji živčani sustav (SŽS).
English: PFS Overall Median (months) (95% CI)
Croatian: PFS Svekupno Medijan (mjeseci) (95% CI)
English: The efficacy and safety of pazopanib in STS were evaluated in a pivotal Phase III randomised, double-blind, placebo-controlled multicentre study (VEG110727).
Croatian: Sigurnost i djelotvornost pazopaniba u STS-u procijenjena je u ključnom randomiziranom, dvostruko slijepom, placebom kontroliranom multicentričnom ispitivanju faze III (VEG110727).
English: Not all pack sizes or tablet strengths may be available in your country.
Croatian: Vaše zemlje se ne moraju nalaziti sve jačine tableta ili veličine pakiranja.
English: HR = hazard ratio; ITT = intent to treat; PFS = progression-free survival.
Croatian: HR = omjer hazarda; ITT = namjera liječenja; PFS = preživljenje bez progresije.
English: Patients should be monitored until return to Grade 1 or baseline.
Croatian: Bolesnike treba nadzirati sve dok se vrijednosti ne vrate na 1. stupanj ili na početnu vrijednost.
English: They are supplied in bottles of 30 or 60 tablets.
Croatian: Pakirane su u boce s 30 ili 60 tableta.
English: 800 mg OD 33.5
Croatian: 800 mg JD 33,5
English: Take it at least two hours after a meal, or one hour before a meal.
Croatian: Uzmite ga najmanje dva sata nakon obroka ili jedan sat prije obroka.
English: Caution is advised in patients with creatinine clearance below 30 ml/min as there is no experience of pazopanib in this patient population.
Croatian: Preporučuje se oprez u bolesnika s klirensom kreatinina nižim od 30 ml/min jer ne postoji iskustvo o primjeni pazopaniba u toj populaciji bolesnika.